Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

NCT06801821 | Recruiting

• 1 other identifier: 7261
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.

• Compare the social distance and stereotyping by the general population toward individuals with facial involvement by: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.
• Evaluate demographic factors that describe a greater tendency toward stigmatization.

Conditions

Psoriasis (PsO); Vitiligo Vulgaris; Atopic Dermatitis; Areata Alopecia

Outcome Measures

Primary Outcomes (1)

• primary endopoint

  Compare the percentage of patients associating the 4 different emotional reactions analyzed (compassion/pity, disgust, blame/disapproval/dislike, and curiosity) with each dermatologic condition under study.

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The intent of this observational study is primarily descriptive. It is estimated to be able to enroll 400 subjects adhering to the inclusion and exclusion criteria under treatment at the dermatology laboratory. Patients will be enrolled consecutively from 01-02-2025 to 01-02-2026. The 400 patients will answer initial questions about the emotional reactions induced by the 4 diseases and SYNOPSIS\_STYGMADERM Study Version 1.0 on 03.10.24 Page 4 of 6 then will answer the questionnaire on stigma toward only one of the 4 dermatologic diseases under study (100 will answer the questionnaire on atopic dermatitis, 100 on alopecia areata, 100 on vitiligo, and 100 on psoriasis).

You may qualify if:

• Patients aged\>18 years, both sexes;
• Signature of written informed consent;

You may not qualify if:

• Patients diagnosed with psoriasis, atopic dermatitis, vitiligo or alopecia areata.
• Patients with first-degree relatives with psoriasis, atopic dermatitis, vitiligo or alopecia areata
• Those who for professional or personal reasons have direct knowledge of the diseases in question.

Sponsors & Collaborators

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: lead

Study Sites (1)

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia

Roma, Italia, 00168, Italy

RECRUITING

MeSH Terms

Conditions

Psoriasis; Vitiligo; Dermatitis, Atopic; Alopecia

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Hypopigmentation; Pigmentation Disorders; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Hypotrichosis; Hair Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Giacomo Caldarola, MD

  Fondazione Policlinico Universitario A. Gemelli, IRCCS

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Caldarola

CONTACT

+390630155284; giacomo.caldarola@unicatt.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 24, 2025
• First Posted: January 30, 2025
• Study Start: February 1, 2025
• Primary Completion: February 1, 2026
• Study Completion: March 1, 2026
• Last Updated: August 26, 2025

Record last verified: 2025-01

Locations

IT (1)